Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The innovation arm of Oxford University gains impact at board level with the addition of the former Minister for Public Health and Innovation and the former Chief Executive of Oxford Instruments.

Nicola Blackwood, the former Minister for Public Health and Innovation and MP for Oxford West and Abingdon, and Jonathan Flint, the former chief executive of the University’s first spinout company Oxford Instruments, have joined Oxford University Innovation’s (OUI) board as non-executive directors.

Nicola Blackwood was Chair of the Science & Technology Select Committee while in Parliament. There, she led inquiries into the science budget, big data, digital skills, space and satellites, and how UK science would be affected by the EU Referendum. As Minister for Public Health and Innovation, she held a portfolio that covered life sciences, mental health, global health security, and public health. Since leaving office, she has taken up a number of board roles, and acts as an advisor to innovation-focused companies.

Jonathan Flint is the President Elect of the Institute of Physics and the former Chief Executive Officer of Oxford Instruments. He has held managing director positions at BAE Systems, Vislink and EADS. At present, Jonathan holds board positions with Stadium plc, the Oxford Trust, and now OUI.

Find out more (Oxford University Innovation website)

Similar stories

AIMday in Experimental Medicine in Psychiatry - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Experimental Medicine in Psychiatry.

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Innovation award for Professor Anindita Roy to develop new treatments for childhood cancer

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.